p-EGFR Antibody (10G12): sc-81487

p-EGFR Antibody (10G12) is a mouse monoclonal IgG3 antibody that detects phosphorylated epidermal growth factor receptor (EGFR) in human samples through applications such as western blotting (WB) and immunoprecipitation (IP). Anti-EGFR antibody (10G12) is raised against a synthetic phosphopeptide surrounding tyrosine 1148 of EGFR of human origin. EGFR is primarily located on the cell surface, where EGFR functions as a receptor for epidermal growth factors, mediating various cellular processes including proliferation, differentiation, and survival. EGFR′s location enables transduction of extracellular signals into intracellular responses, initiating cascades that lead to cell division and tissue repair. Dysregulation of EGFR signaling is implicated in numerous cancers, as mutations or overexpression can result in uncontrolled cell proliferation and survival, driving tumorigenesis. Constitutive activation of EGFR is associated with enhanced metastatic potential, enabling cancer cells to invade surrounding tissues and establish secondary tumors. Aberrant EGFR signaling can confer resistance to conventional therapies, further complicating cancer treatment and underscoring the need for targeted therapeutic strategies. Phosphorylation of specific tyrosine residues on EGFR, such as Tyr 1092 and Tyr 1173, is essential for activation and subsequent signaling, highlighting the importance of monitoring these modifications in research and clinical settings. EGFR monoclonal antibody (10G12) enables researchers to gain valuable insights into the mechanisms of EGFR activation and implications in various diseases, particularly in cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-EGFR Antibody (10G12) References:

1. Association of the tyrosine phosphorylated epidermal growth factor receptor with a 55-kD tyrosine phosphorylated protein at the cell surface and in endosomes.  |  Wada, I., et al. 1992. J Cell Biol. 116: 321-30. PMID: 1370492
2. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas.  |  Hiraishi, Y., et al. 2006. Pathol Oncol Res. 12: 87-91. PMID: 16799709
3. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients.  |  Hammarsten, P., et al. 2010. Clin Cancer Res. 16: 1245-55. PMID: 20145160
4. Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma.  |  Nijkamp, MM., et al. 2011. Radiother Oncol. 101: 165-70. PMID: 21775008
5. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR.  |  Wang, F., et al. 2012. J Exp Clin Cancer Res. 31: 65. PMID: 22901364
6. Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis.  |  Shan, ZZ., et al. 2017. Oncol Lett. 14: 2859-2863. PMID: 28927043
7. Dysregulated Expression of Phosphorylated Epidermal Growth Factor Receptor and Phosphatase and Tensin Homologue in Canine Cutaneous Papillomas and Squamous Cell Carcinomas.  |  Sanz Ressel, BL., et al. 2020. J Comp Pathol. 174: 26-33. PMID: 31955800
8. Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis.  |  Hong, X., et al. 2022. Medicine (Baltimore). 101: e28507. PMID: 35060503
9. GLUT1 promotes cell proliferation via binds and stabilizes phosphorylated EGFR in lung adenocarcinoma.  |  Zhou, Z., et al. 2024. Cell Commun Signal. 22: 303. PMID: 38831321
10. Inhibition of binding of phospholipase C gamma 1 SH2 domains to phosphorylated epidermal growth factor receptor by phosphorylated peptides.  |  McNamara, DJ., et al. 1993. Int J Pept Protein Res. 42: 240-8. PMID: 8225779

The preferred EGFR antibody is EGFR Antibody (528): sc-120.